01376nam a2200241   4500001000800000005001700008007000300025008004100028040000800069041000800077100003300085245006200118300002500180520066400205650002200869650002100891650001800912650001700930650003600947650002500983700002301008773010301031ESSALUD20260902150847.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aSpyropoulos, Alex C. eAutor  aAdvanced Therapy for Intermediate-Risk Pulmonary Embolism  apáginas: 2052-2054  aPulmonary embolism is the third leading cardiovascular cause of complications and death after myocardial infarction and stroke, with a rising incidence globally. The approach to management of acute pulmonary embolism as a condition to be treated nonsurgically with systemic heparin anticoagulation was established more than 60 years ago. Patients with high-risk pulmonary embolism and cardiogenic shock appear to benefit from early thrombus removal, with rapid reductions in pulmonary obstruction and pulmonary vascular resistance from baseline and a lower risk of death than with anticoagulation alone, but at the cost of a nearly 10% risk of major bleeding.  aANTICOAGULACIÓN  aTROMBOEMBOLISMO   aCARDIOLOGÍA  aNEUMOLOGÍA  aMEDICINA CLÍNICA HOSPITALARIA  aRADIOLOGÍA GENERAL  aVedantham, Suresh 0 022717dMassachusetts NEJM GroupoNEJM013tThe New England Journal of Medicine wESSALUDx0028-4793